A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
Completed
- Conditions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40563
- Registration Number
- NCT06683768
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT06675864
Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study
Completed
- Conditions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1603
- Registration Number
- NCT06669221
- Locations
- 🇯🇵
Novartis, Tokyo, Japan
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06668324
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
Completed
- Conditions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 232
- Registration Number
- NCT06666114
- Locations
- 🇧🇷
Novartis, Sao Paulo, Brazil
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT06665256
- Locations
- 🇺🇸
University Of Iowa, Iowa City, Iowa, United States
🇯🇵Novartis Investigative Site, Sapporo city, Hokkaido, Japan
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT06659393
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT06655896
- Locations
- 🇺🇸
University Of Iowa, Iowa City, Iowa, United States
🇸🇬Novartis Investigative Site, Singapore, Singapore
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 232
- Registration Number
- NCT06649110
- Locations
- 🇺🇸
PPD Development LP, Austin, Texas, United States
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT06643481
- Locations
- 🇺🇸
Nerve and Muscle Center of Texas, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath